Physician profile
David M Henkel
NPI 1730574567
$1,038.11
in general payments reported to CMS, 2019-2025
11 companies · $71.52 in 2025
The $71.52 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $33.79 · 2021: $224 · 2022: $294 · 2023: $110 · 2024: $29.42 · 2025: $71.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $210.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $348.92 | 2019-2022 | |
| Abbvie INC. | $178.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $129.81 | 2021-2024 | Andexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.45 | 2019-2025 | Xifaxan |
| Portola Pharmaceuticals, LLC | $115.42 | 2019 | |
| Vifor Pharma, INC. | $42.94 | 2021 | |
| Gilead Sciences, INC. | $32.85 | 2021-2023 | |
| Stryker Corporation | $25.23 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Allergan, INC. | $19.46 | 2020 | |
| Chiesi USA, INC. | $14.26 | 2025 | Cleviprex |
| Pfizer INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Henkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.